Nociceptive transmission and modulation via P2X receptors in central pain syndrome by Yung-Hui Kuan & Bai-Chuang Shyu
REVIEW Open Access
Nociceptive transmission and modulation
via P2X receptors in central pain syndrome
Yung-Hui Kuan and Bai-Chuang Shyu*
Abstract
Painful sensations are some of the most frequent complaints of patients who are admitted to local medical clinics.
Persistent pain varies according to its causes, often resulting from local tissue damage or inflammation. Central
somatosensory pathway lesions that are not adequately relieved can consequently cause central pain syndrome or
central neuropathic pain. Research on the molecular mechanisms that underlie this pathogenesis is important for
treating such pain. To date, evidence suggests the involvement of ion channels, including adenosine triphosphate
(ATP)-gated cation channel P2X receptors, in central nervous system pain transmission and persistent modulation
upon and following the occurrence of neuropathic pain. Several P2X receptor subtypes, including P2X2, P2X3, P2X4,
and P2X7, have been shown to play diverse roles in the pathogenesis of central pain including the mediation of
fast transmission in the peripheral nervous system and modulation of neuronal activity in the central nervous
system. This review article highlights the role of the P2X family of ATP receptors in the pathogenesis of central
neuropathic pain and pain transmission. We discuss basic research that may be translated to clinical application,
suggesting that P2X receptors may be treatment targets for central pain syndrome.
Keywords: Central pain syndrome, Adenosine triphosphate (ATP), P2X receptors
Background
According to the International Association for the Study
of Pain (IASP), central neuropathic pain is commonly
caused by lesions or disease of the central somatosen-
sory nervous system (e.g., brain trauma, stroke, multiple
sclerosis, spinal cord injury, syringomyelia, syringobul-
bia, tumors, and abscesses) or other inflammatory cen-
tral nervous system (CNS) diseases [1]. The National
Institute of Neurological Disorders and Stroke (NINDS)
notes that central pain syndrome is a neurological condi-
tion that is caused by damage to or dysfunction of the
CNS, including the brain, brainstem, and spinal cord.
This syndrome can be caused by stroke, multiple scler-
osis, tumors, epilepsy, brain or spinal cord trauma, or
Parkinson’s disease [2].
Because of the wide variety of potential causes, the
characteristics of pain that is associated with this syn-
drome differ widely among individuals. According to the
NINDS, central pain syndrome can affect both specific
areas, such as the hands or feet, or a large portion of the
body. Prolonged pain is usually related to the cause of
CNS injury, and the resulting central pain is typically
perceived as constant, with moderate to severe intensity,
and often made worse by touch, movement, and changes
in temperature. Individuals might experience one or
more types of pain sensations, the most prominent of
which is a burning sensation that is sometimes com-
bined with sensations of pressing, laceration, or aching
and brief, intolerable bursts of sharp pain. Such sharp
pain is similar to the pain that may be caused by a dental
probe that touches an exposed nerve [2]. Individuals
may also experience numbness in areas that are affected
by this pain syndrome. Some individuals claim that
burning feelings and loss-of-touch sensations are usually
most severe in distal parts of the body, such as the hands
and feet. Central pain syndrome often begins shortly
after the causal injury or damage but may be delayed by
months or even years, especially if it is related to post-
stroke pain [2].
Molecular studies, particularly focused on ion chan-
nels that are related to plasticity in the nociceptive som-
atosensory system, may enable the development of new
pharmacological treatments against central pain syndrome.
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To date, evidence suggests the involvement of various ion
channels in the pathogenesis of central pain, including so-
dium channels, calcium channels, potassium channels,
acid-sensing ion channels, and adenosine triphosphate
(ATP)-gated cation channels [3–7]. In this review, we focus
on the involvement of ATP-gated cation channel P2X re-
ceptors in central nervous system pain transmission and
persistent modulation upon and following the occurrence
of central neuropathic pain. We discuss basic research that
may be translated to clinical application, suggesting that
P2X receptors may be treatment targets for central pain
syndrome.
Adenosine triphosphate and the involvement of P2X
Receptors in neuropathic pain
Adenosine triphosphate (ATP) is a well-known energy
provider for cellular function. It was discovered to act as a
neurotransmitter in the early 1970s [8]. This opened the
way for studies on purinergic signaling and related recep-
tors, thus spurring the field of purinergic neurotransmis-
sion [9]. In the CNS, ATP serves as a signaling molecule
that modulates communication between neurons and glial
cells. Cellular responses to trauma and ischemia that are
trigged by ATP are important for initiating and maintain-
ing reactive astrogliosis, which may result in changes in
the proliferation and morphology of astrocytes and micro-
glia [10]. A small amount of ATP that is released during
brain injury is neuroprotective; at higher concentrations,
however, ATP can contribute to pathogenic processes
[11]. Channel characterization provided a basis for distin-
guishing two types of purinoceptors, P1 and P2. P1 recep-
tors are specific to nucleosides, and P2 receptors are
specific to nucleotides [12]. P1 receptors are G protein-
coupled receptors, and P2 receptors can be divided into
P2X ion channel receptors and P2Y G protein-coupled re-
ceptors [13].
P2X receptors attracted scientific interest in pain re-
search with early observations that ATP itself evokes pain
when applied to blisters [14, 15]. Accumulating evidence
indicates that this effect is mediated by the activation of
P2X3 receptors, which are restricted in their distribution
to a subset of primary afferent neurons [15–17] that also
express receptors for capsaicin (TRPV1) and isolectin B4
[15, 18, 19]. P2X3 receptors also play a role in visceral
mechanosensory transduction. Distension-induced stimu-
lation of P2X3 receptors that are expressed on primary
sensory afferents in the urothelium was shown to result in
ATP release, leading to an increase in afferent nerve activ-
ity. P2X3 knockout mice and animals with alterations in
P2X3 levels exhibited a decrease in afferent nerve activity
and a reduction of nociceptive signaling [20, 21]. Previous
reviews suggested that P2X3 receptors and the P2X2/3 re-
ceptor complex play crucial roles in mechanosensory
transduction and nociception [22]. Antagonists that are
selective for P2X3-containing receptors have been shown
to reduce chronic neuropathic and inflammatory pain in
rats [23]. The downregulation of P2X3 receptor expres-
sion by intrathecal antisense oligonucleotide administra-
tion or local administration of the P2X2/3 antagonist A-
317491 reduced mechanical hyperalgesia that was evoked
by carrageenan [24] and complete Freund’s adjuvant [25].
These studies demonstrated that ATP acts on P2X2/3 re-
ceptors that are expressed on peripheral nerve afferents as
a component of the local inflammatory response.
Models of neuropathic pain have revealed that both lo-
cally and intrathecally applied selective P2X3 receptor
antagonists can prevent mechanical allodynia [26, 27].
When applied locally, P2X3 antagonists cause
sensitization and an increase in the expression of mem-
brane P2X3 receptors, rather than an increase in ATP
release [28].
P2X4 receptors that are expressed in the CNS have
been proposed to be involved in the pathogenesis of
neuropathic pain [29]. The development of oversensitiv-
ity to mechanical stimuli following peripheral nerve in-
jury was prevented by P2X4 receptor depletion, and
allodynia that occurs post-nerve injury may be reduced
by targeting P2X4 receptors [30–32]. The activation of
spinal microglia is known to occur following peripheral
nerve injury. Evidence suggests that ATP acts on P2X4
receptors to drive the release of brain-derived neuro-
trophic factor (BDNF) from spinal microglia, which is a
critical response for neuronal tissue rewiring that under-
lies the perception of mild tactile stimuli as noxious
[32].
P2X7 receptors have been shown to modulate behav-
ioral responses to painful stimuli [33, 34]. In contrast to
P2X4 receptors, pharmacological antagonists of P2X7
receptors are available as experimental tools, and some
of these have been tested in clinical trials [26, 35]. P2X7
receptors are predominantly expressed on microglia, as-
trocytes, and oligodendrocytes in the nervous system.
However, some reinterpretation of the data from experi-
ments that used P2X7 knockout mice is required. P2X7
knockout mice that are referred to as the Pfizer line
(generated by Solle and colleagues [36]) continue to ex-
press two alternatively spliced and shortened forms of
P2X7 receptors (i.e., P2X7 13B and P2X7 13C). P2X7
knockout mice that are provided by Glaxo continue to
express a functional P2X7 splice variant (P2X7k), and
the corresponding protein is widely expressed but has a
different N-terminus and transmembrane domain 1
(TM1) [37]. The P2X7k splice variant forms receptors
that are more sensitive to ATP and undergo a rapid in-
crease in permeability to organic cations, a measure of
pore dilation [37].
In models of neuropathic pain, the development of
mechanical hypersensitivity is absent in Glaxo P2X7
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knockout mice [38]. A similar phenotype is observed in
mice that lack both isoforms of interleukin-1β (IL-1β)
[39]. Intrathecal administration of the P2X7 antagonist
A-438079 may prevent mechanical hypersensitivity [40],
and the same phenomenon was observed with systemic
administration of Brilliant Blue G (BBG) [41] and sys-
temic administration of other P2X7 receptor antagonists
[42]. These effects in models of pain appear to require
the release of IL-1β. A-438079 was shown to block both
the ATP- and lipopolysaccharide (LPS)-induced release
of IL-1β [43]. Indeed, the LPS-induced release of IL-1β
is absent in lumbar spinal cord slices from P2X7 knock-
out mice. These results suggest that the rewiring of
microcircuitry in the spinal cord that occurs during pro-
longed inflammation or nerve injury may require the in-
volvement of sequential signaling that is initiated with
ATP release, followed by the activation of P2X7 recep-
tors on spinal microglia and release of IL-1β. Our under-
standing of the source of ATP has not advanced much
since Pamela Holton showed that sensory nerves release
ATP in response to electrical stimulation [44]. IL-1β re-
lease that is caused by nerve injury or prolonged inflam-
mation has been suggested to lead to an increase in the
phosphorylation of the NR1 and NR2B subunits of the
N-methyl-D-aspartate receptor and perhaps an LTP-like
phenomenon [45]. Such responses have been associated
with behavioral hyperalgesia [46].
P2X7 receptors have been considered a potential target
for pain therapies, which is supported by genetic associ-
ation studies. The function of a particular form of mouse
P2X7(P451L) receptors is impaired when measured by
the ATP-evoked uptake of YO-PRO-1 (i.e., a commonly
used optical measure of pore dilation) but not when
measured by ATP-induced ionic currents [47, 48]. The
H155Y and R270H polymorphisms of P2X7 receptors
are known to result in an increase and decrease in P2X7
receptor function, respectively. The H155Y and R270H
polymorphisms of P2X7 were shown to be expressed
more often in subjects who reported higher and lower
levels of pain, respectively, following mastectomy [49].
These authors utilized seven inbred strains, each with
different P2X7 alleles that resulted in various single-
nucleotide polymorphisms (SNP). Six strains that carried
the Leu451 allele presented significantly lower allodynia
compared with strains that carried the Pro451 allele
[49].
P2X receptors and neuropathic pain caused by spinal
cord injury
Adenosine triphosphate has been shown to be a key
element in relaying sensory information from the per-
iphery to the CNS [50], in addition to being one of sev-
eral important mediators of immune-neural interactions
[51]. Both sensory neurons and glial cells inside and
outside the CNS release ATP to affect surrounding cells
[52, 53]. Accumulating evidence suggests a link between
activated microglia and astrocytes, central sensitization,
and the development and maintenance of neuropathic
pain [53–55]. Spinal cord injury is often complicated by
secondary injury as a result of the innate inflammatory
response to tissue trauma and swelling. In the setting of
spinal cord injury, ATP release increases in peritrau-
matic areas for > 6 h [56]. Below we discuss studies of
the involvement of P2X receptors in neuropathic pain
that is caused by spinal cord injury.
P2X3 receptors were shown to be expressed on rat
sensory neurons in naive animals, and immunohisto-
chemistry revealed elevations of P2X3 receptor expres-
sion in the superficial laminae of the dorsal horn
following nerve injury [57]. A significant increase in the
number of nodose ganglion neurons that expressed
P2X3 was found upon spinal cord injury, a finding that
matched also for the bladder-innervating vagal afferents,
because most viscera, including the bladder, are dually
innervated by spinal and vagal sensory neurons and the
impacts of spinal cord injury on the sensory component
of vagal circuitry was shown to have a significant in-
crease in the number of NG neurons expressing P2X3
and this may contribute to visceral pathologies following
spinal cord injury [58]. Munoz and colleagues found that
changes in bladder afferent signals in normal and spinal
cord-injured rats may be modulated by purinergic P2X3
and P2X2/3 receptors [59]. These studies indicate that
vagal afferents, including those that innervate the blad-
der, exhibit neurochemical plasticity after spinal cord in-
jury, which may elucidate the visceral homeostatic
mechanisms and nociceptive signaling that are related to
the involvement of P2X3 and P2X2/3 receptors. A novel
non-nucleotide antagonist of P2X3 receptors and the
P2X2/3 receptor complex was shown to block native
P2X3 and P2X2/3 receptors on rat dorsal root ganglion
neurons and attenuate both thermal hyperalgesia and
mechanical allodynia after chronic spinal cord injury
[23].
Tsuda and colleagues reported that P2X4 receptors are
expressed in neurons in the spinal cord [30]. Later reports
provided direct evidence that spinal cord injury causes an
innate inflammatory response that leads to an increase in
caspase-l cleavage and the production of IL-1β [32, 50, 51,
60]. P2X4 knockout mice exhibited impairments in
inflammasome signaling in the spinal cord, resulting in a
decrease in the levels of IL-1β, reductions of the infiltra-
tion of neutrophils and monocyte-derived M1 macro-
phages, significant tissue sparing, and improvements in
functional outcomes [29, 31, 32]. These results indicate
that P2X4 receptors influence inflammasome signaling,
caspase-1 activation, and IL-1β processing in neurons
after spinal cord injury. Thus, P2X4 receptors might be a
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potential therapeutic target to limit inflammatory re-
sponses that are associated with spinal cord injury and
neurodegenerative disorders [29, 60].
P2X7 receptors were shown to be elevated after spinal
cord injury as well, inhibition of this elevation of P2X7
resulted in improvements in the recovery from spinal
cord injury in a rat model [56]. P2X7 receptor activation
was observed in a weight-drop model of thoracic spinal
cord injury in rats, and systemic administration of the
P2X7 receptor antagonist BBG exerted neuroprotective
effects. The administration of BBG within 15 min after
injury reduced tissue damage in the spinal cord and im-
proved motor recovery without causing overt cellular/
tissue toxicity [61].
These reports indicate that P2Xs are expressed on sen-
sory neurons in the spinal cord and are activated after
various forms of spinal cord injury, and subsequent ATP
signaling is involved in the pathogenesis of central
neuropathic pain.
P2X receptors and central post-stroke pain
Central post-stroke pain (CPSP) is defined by the IASP
as a central neuropathic pain condition, in which pain
arises as a direct result of cerebrovascular lesions in the
central somatosensory nervous system [2]. To date, few
reports have investigated the involvement of P2X recep-
tors in CPSP. Some studies have reported that peripheral
ATP and purinergic P2X receptors on sensory nerve ter-
minals contribute to spinal cord sensitization, which
may be involved in CPSP-related behavior [62]. Micro-
glia express numerous purinergic receptors. P2X4 and
P2X7 receptors have been shown to play important roles
in central neuropathic pain via microglia activation [63–
65]. The inhibition of P2X4 receptors after nerve injury
has been shown to prevent the upregulation of P2X4 re-
ceptors in the dorsal horn, alleviate mechanical allodynia
[66], and influence the progression of traumatic injury in
the CNS [67, 68]. The genetic elimination of P2X7 re-
ceptors resulted in a decrease in neuropathic pain, but
unclear is whether this effect is specifically mediated by
microglia, particular subtypes of central neurons within
specific microcircuitry, or peripheral cell types [38, 69].
Functional involvement of P2X7 receptors in CPSP
A recent study by our group investigated the involvement
of P2X7 receptors in a rat model of CPSP and the mecha-
nisms that are involved in the activation of P2X7 receptor
pathways in the pathogenesis of CPSP. A thalamic
hemorrhagic rat model was used, in which type IV collage-
nase was injected into the right lateral thalamus. Behavioral
tests, electrophysiological recordings, and microdialysis
were performed to elucidate the characteristics of CPSP.
Systemic and local pharmacological interventions were
used to interrupt P2X7 receptor activation. Spontaneous
pain and thermal and mechanical hyperalgesia developed in
the subacute to chronic phases in rats that were subjected
to lateral thalamic hemorrhage. Immunostaining at 5 weeks
post-hemorrhage revealed significant activation of P2X7 re-
ceptors in microglia along thalamic peri-lesion tissue. In-
creases in the immunoreactivity of P2X7 receptors and the
reactive microglia marker CD11b were largely localized to
peri-lesion sites in CPSP rats, whereas their immunoreac-
tivity remained at basal levels in the contralateral site and
sham control rat brains. Significant increases in the counts
of cells that were immunoreactive to both P2X7 and
CD11b in a selected region of interest were observed. Tis-
sue samples from the peri-lesion sites were screened using
quantitative reverse-transcription polymerase chain reac-
tion. The levels of tumor necrosis factor α (TNF-α), IL-6,
and BDNF significantly increased in peri-lesion tissues
compared with unaffected contralateral sites. The proin-
flammatory cytokine IL-1β directly downstream of P2X7
receptor activation also exhibited a prominent elevation.
Thalamocingulate circuitry in the CNS is known as a
medial pain processing pathway. Changes in nociceptive
sensitivity in the forebrain under conditions of neuro-
genic pain likely result from aberrant neuronal activity
along this pathway, reflected by thalamocortical dys-
rhythmia [70–72]. To test the hypothesis that persistent
pain in CPSP rats is accompanied by changes in noci-
ceptive sensitivity, multichannel electrodes were used to
record evoked neuronal activity in the anterior cingulate
cortex (ACC) and medial thalamus (MT) in response to
sciatic nerve stimulation. Treatment with a P2X7 recep-
tor antagonist during the acute stage of hemorrhage res-
cued abnormal pain behaviors and neuronal activity in
the thalamocingulate pathway by reducing microglial ag-
gregation and associated inflammatory cytokines. Aber-
rant spontaneous thalamocortical oscillations after lateral
thalamic hemorrhage could be regulated by blocking
P2X7 receptors. These findings suggest that P2X7 recep-
tors may be a potential target for preventing the occur-
rence of CPSP in patients with acute stroke [73].
Figure 1 illustrates our concepts regarding P2X7 re-
ceptor in normal and CPSP states, combined with previ-
ous reports of P2X4 and P2X7 receptor function and
their role in other types of neuropathic pain. Both of
these receptor subtypes have been shown to be highly
involved in neuropathic inflammatory pain [29–35]. In
the normal state, P2X4 and P2X7 receptor expression is
low in neurons, astrocytes, glia cells, and resting micro-
glia cells. In CPSP, however, the pathological enhance-
ment of ATP release to surrounding tissue after stroke
insult may lead to an increase in both P2X4 and P2X7
receptor expression and activation. Such activation has
been reported to promote synaptic glutamate release and
the abnormally high production of IL-1β [74–76], TNF-α,
and BDNF [24–27]. Consequently, IL-1β has been
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reported to alter glutamate transmission in the CNS [77],
and BDNF has been shown to alter chloride ion flux via
TrkB and γ-aminobutyric acid receptors [78]. Such se-
quential elevations of signaling molecules at sites of dam-
age, combined with blood cell infiltration, can affect the
activity of astrocytes, microglia, and neurons, thus result-
ing in neuronal hyperexcitability that is promoted periph-
eral pain sensitivity and contributing to the pathogenesis
of CPSP.
Prospective therapeutic implications
The P2X family of ATP receptors is widely expressed in
various tissues. P2X2, P2X3, P2X4, and P2X7 receptors
are more abundant in central and peripheral neurons
[79–81]. Under pathological conditions, ATP is the most
powerful mediator of P2X receptor activation. P2X re-
ceptors, including neuronal P2X3 receptor subtypes and
P2X4 and P2X7 receptors that are expressed on non-
neuronal cells, behave as sensitive ATP detectors. Dis-
secting the molecular mechanisms in sensory neurons
and accessory cells may contribute to the development
of tissue- and cell-targeted approaches to treat chronic
pain and inflammatory diseases [82]. P2X3, P2X4, and
P2X7 receptor antagonists have been shown to have
antinociceptive and antiinflammatory effects in animal
models of these diseases [38, 56, 62, 63, 65, 83, 84]. As
illustrated in Fig. 1, a logical proposal is that targeting
P2X7 receptors after the onset of CPSP may block the
hyperexcitability that is observed in thalamocingulate
pathways and block the abnormal elevation of P2X7 re-
ceptor activation, culminating in the prevention of ab-
normal glutamate release and IL-1β secretion and
modulation of neuronal activity and behavioral pain
under conditions of CPSP.
Central pain syndrome is a substantial clinical prob-
lem, but the currently available treatments are unable to
Fig. 1 Schematic illustration of P2X7 receptor involvement in sequential signaling effects on microglia and neuronal activity in CPSP. The figure
illustrates our concepts of the involvement of P2X7 receptor in normal and CPSP states, combined with previous reports of P2X4 and P2X7
receptor function and their roles in other types of neuropathic pain. In the normal state, P2X4 and P2X7 receptor expression is low in neurons,
astrocytes, glia, and resting microglial cells. In the CPSP state, the pathological enhancement of ATP release to surrounding tissue after stroke
insult may lead to an increase in both P2X4 and P2X7 receptor expression and activation. Such activation has been reported to promote synaptic
glutamate release and the abnormally high production of IL-1β, TNF-α, and BDNF. Consequently, IL-1β has also been reported to alter glutamate
transmission in the CNS, and BDNF has been shown to alter chloride ion flux via TrkB and GABA receptors. Such sequential elevations of signaling
molecules at sites of damage, combined with blood cell infiltration, can affect the activity of astrocytes, microglia, and neurons, thus resulting in
neuronal hyperexcitability that is promoted by peripheral pain sensitivity and leading to the pathogenesis of CPSP. Figure adapted from Kuan et
al. [68]
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provide sufficient pain relief for patients who suffer from
the chronic phase of this condition. Previous studies by
our group suggest the possibility of targeting P2X7 re-
ceptors during the initial onset of stroke or delaying
treatment until CPSP is manifest in the subacute to
chronic phase. In stroke patients who already suffer
from CPSP, agents that target P2X7 receptors may exert
antinociceptive effects by suppressing or blocking neur-
onal hyperexcitability and reversing abnormal oscilla-
tions. Early treatment with a P2X7 receptor antagonist
in stroke patients may prevent the activation of P2X7 re-
ceptors that are expressed on microglia/monocyte-de-
rived macrophages in peri-lesion tissues, thus reducing
the release of regional inflammatory cytokines and associ-
ated neuronal damage. Importantly, commercially avail-
able P2X7 receptor antagonists are usually small-molecule
compounds with good blood–brain barrier permeability
when administered peripherally. We found that systemic
infusion of BBG did not cause apparent toxicity, which
confirms previous findings [61] and suggests that similar
compounds that target various P2X receptors may be
therapeutic candidates for the treatment of central pain
syndromes that are caused by brain trauma.
Conclusion
The overall complexity of the plasticity of pain recep-
tors, the sensitization of sensory neurons, and mediators
that are released from non-neuronal cells has hindered
our understanding of the spatial and temporal develop-
ment of pain, neuronal responses, and disease progres-
sion. We have primarily focused on the involvement of
P2X receptors in central neuropathic pain that is caused
by nerve injury. Sites of the expression of these P2X
receptors and pharmacological, molecular, and genetic
manipulations of their function have reveled clear influ-
ences on nerve injury-induced pain behaviors and hyper-
excitability of the central pain pathway. P2X3 receptors
play a significant role in neuropathic and inflammatory
pain. Long-lasting allodynia that is produced by intra-
thecal administration of ATP likely occurs through
Fig. 2 Schematic illustration of P2X receptors involvement in nociceptive transmission and modulation in central pain syndrome. Adenosine
triphosphate is an important soluble mediator that is involved in cross-talk between sensory neuron synapses within ascending nociceptive
transmission pathways. P2X receptors are expressed in the presynaptic membrane, postsynaptic density, astrocytes, and microglia. In the central pain
state, abnormal neuronal excitability and enhanced glutamate/ATP release activate postsynaptic neurons, microglia, and astrocytes, thus contributing
to central sensitization and the release of inflammatory mediators and neurotrophins. Currently available evidence strongly suggests a key modulatory
role of P2X receptors in central sensitization. Primary nociceptive inputs promote glutamate and ATP co-release and synergistically cause non-selective
permeability to Ca2+, Na+, and K+ ions via P2X receptors, leading to the postsynaptic activation of NMDA or AMPA receptors and further contributing
astrocytic glutamate and ATP co-release into the extracellular milieu. Intracellular astrocytic Ca2+ signals may spread within astrocytes, leading to similar
effects at other synapses. Local brain tissue damage resulted ATP release and inflammation can also activate extrasynaptic P2X receptors on microglia.
P2X receptors expressed on astrocytes and microglia induces a local inflammatory response with release of cytokines. P2X7 has many consequences in
pain, for its role in the inflammasome activation and maturation of IL-1β, one of the most powerful mediators of acute inflammatory response. P2X4
was reported to induce release of BDNF, acting on TrkB receptor which modulates inhibitory neurons, contributing to exacerbation of painful signal
transmission pathways in brain centers. Both synaptic and glial release of glutamate and the co-release of neuronal, astrocytic and microglial ATP
contribute to synaptic transmission via P2X receptors
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P2X2/3 receptors. Spinal P2X2 and P2X3 receptors have
been reported to be involve in neuropathic pain in a
mouse model of chronic constriction injury. Dorsal horn
neurons relay nociceptive information along the pain
pathway via P2X4 receptors. P2X receptor activation in
the spinal cord may elicit allodynia, and the upregulation
of P2X4 receptors in spinal cord microglia appears to
play a dominant role in this effect. P2X7 receptors, via
the regulation of IL-1β production, play an upstream
transductional role in the development of neuropathic
and inflammatory pain. Reviews of the role of P2X7 re-
ceptors in pain and inflammation highlight the potential
therapeutic benefit of modulating P2X7 receptors. How-
ever, the underlying mechanisms that involve microglial
P2X4 and P2X7 receptors are still unclear. The present
review highlights the involvement of the P2X family of
ATP receptors in the pathogenesis of central neuropathic
pain and overall pain transmission. A better understand-
ing of the function and involvement of P2X receptors will
provide useful insights into mechanisms of pain and pos-
sibly new therapeutic agents for the management of
neuropathic pain. P2X receptors should be considered fur-
ther as treatment targets for central pain syndrome.
Figure 2 illustrates our concepts of the involvement of
P2X receptors in nociceptive transmission and modula-
tion in central pain syndrome. Adenosine triphosphate is
an important soluble mediator that is involved in cross-
talk between sensory neuron synapses within ascending
nociceptive transmission pathways. P2X receptors have
been reported to express in the presynaptic membrane,
postsynaptic density, astrocytes, and microglia. In central
pain states, abnormal neuronal excitability and enhanced
glutamate/ATP release activate postsynaptic neurons,
microglia, and astrocytes, thus contributing to central
sensitization and the release of inflammatory mediators
and neurotrophins. Currently available data strongly
suggest a key modulatory role of P2X receptors in cen-
tral sensitization [82, 85]. Primary nociceptive inputs
promote glutamate and ATP co-release and synergistic-
ally cause the release of intracellular Ca2+ within neur-
onal or astrocyte processes, leading to the postsynaptic
activation of N-methyl-D-aspartate (NMDA) or α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors and further astrocytic ATP release into the
extracellular milieu. Local brain tissue damage can activate
extrasynaptic P2X receptors on microglia. Astrocytic Ca2+
signals may spread within astrocytes, leading to similar ef-
fects at other synapses. Microglia activation in responses
to local inflammatory condition resulting release of cyto-
kines. P2X7 has many consequences in pain, for its role in
the inflammasome activation and maturation of IL-1β,
one of the most powerful mediators of acute inflammatory
response. P2X4 was reported to induce release of BDNF,
acting on TrkB receptor which modulates inhibitory
neurons, contributing to exacerbation of painful signal
transmission pathways in brain centers. Both synaptic and
glial glutamate release and the co-release of neuronal,
astrocytic and microglial ATP contribute to synaptic trans-
mission. However, astrocytic and microglial processes have
not yet been shown to actively contribute to synaptic trans-
mission; instead, they exert strong activation-dependent
neuromodulation via ATP. The fine control of P2X recep-
tor activity in different cell types is thus thought to be
necessary for maintaining tissue in a healthy functional
state.
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